Clinical Trials Browser

OTHER × Adenocarcinoma of Lung × Nivolumab × Clear all

NCT03391869 2025-12-17

Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06495125 2025-04-17

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Phase 2 Recruiting

Adenocarcinoma of Lung, Lung Neoplasms

NCT05081674 2023-10-11

BLISS

Phase 2 Completed

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03041181 2022-07-11

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

Phase 2 Terminated

3 enrolled 11 charts

Adenocarcinoma of Lung, Lung Neoplasms

NCT02466568 2019-09-09

Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

Phase 1/2 Withdrawn

Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis